The aim of this study was to evaluate the efficacy of fractional CO2 laser therapy in breast cancer survivors as a therapeutic method for vulvovaginal atrophy (VVA) dyspareunia.
50 patients (mean age 53.3 years) underwent fractional microablative CO2 laser treatment for dyspareunia in oncological menopause (mean time of menopause 6.6 years). The Gloria Bachmann’s Vaginal Health Index (VHI) score was chosen as system to evaluate the presence of VVA and its improvement after the treatment. Intensity of dyspareunia was evaluated using a visual analog scale (VAS).
Data indicated a significant improvement in VVA dyspareunia (p < 1.86e−22) in breast cancer survivors who had undergone 3 sessions of vaginal fractional CO2 laser treatment. Moreover, VHI scores were significantly higher 30 days post-treatment (T4) (p < 0.0001). 76 % of patients were satisfied or very satisfied with the treatment results. The majority (52 %) of patients were satisfied after a long-term follow-up (mean time 11 months). No adverse events due to fractional CO2 laser treatment occurred.
The treatment with fractionated CO2 laser appeared to be a feasible and effective treatment for VVA dyspareunia in breast cancer survivors with contraindications to hormonal treatments.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Nappi RE, Palacios S (2014) Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause. Climateric 17:3–9
Santoro N, Komi J (2009) Prevalence and impact of vaginal symptoms among postmenopausal women. J Sex Med 6:2133–2142
The North American Menopause Society. Management of symptomatic vulvovaginal atrophy (2013) 2013 position statement of The North American Menopause Society. Menopause 20:888–902
Lindau ST, Schumm LP, Laumann EO, Levinson W, O’Muircheartaigh CA, Waite LJ (2007) A study of sexuality and health among older adults in the United States. N Engl J Med 357:762–774
Sturdee DW, Panay N (2010) International Menopause Society Writing Group. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric 13:509–522
Perino A, Calligaro A, Forlani F, Tiberio C, Cucinella G, Svelato A, Saitta S, Calagna G (2015) Vulvo-vaginalatrophy: a new treatment modality using thermo-ablative fractional CO2 laser. Maturitas 80:296–301
Salvatore S, Nappi RE, Zerbinati N, Calligaro A, Ferrero S, Origoni M, Candiani M, Leone Roberti Maggiore U (2014) A 12-week treatment with fractional CO2 laser for vulvovaginal atrophy: a pilot study. Climateri 17:363–369
Committee on Gynecologic Practice, American College of Obstetricians and Gynecologists. ACOG Committee Opinion No. 378 (2007) Vaginal “rejuvenation” and cosmetic vaginal procedures. Obstet Gynecol 110:737–738
Panda S, Das A, Singh AS, Pala S (2014) Vaginal pH: a marker for menopause. J Midlife Health 5:34–37
Moradan S, Ghorbani R, Nasiri Z (2010) Can vaginal pH predict menopause? Saudi Med J 31:253–256
Persu C, Chapple CR, Cauni, V, Gutue S, Geavlete P (2011) Pelvic organ prolapse quantification system (POP–Q)—a new era in pelvic prolapsed staging. J Med Life 75–81
Bachmann GA, Notevolitz M, Kelly SL (1992) Long-term non-hormonal treatment of vaginal dryness. Clin Pract Sex 8:3–8
Wysocki S, Kingsberg S, Krychman M (2014) Management of vaginal atrophy: implications from the Revive survey. Clin Med Insights Reprod Health 8:23–30
Constantine G, Graham S, Koltun WD, Kingsberg SA (2014) Assessment of ospemifene or lubricants on clinical signs of VVA. J Sex Med 11:1033–1041
Portman D, Palacios S, Nappi RE, Mueck AO (2014) Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial. Maturitas 78:91–98
Gaspar A, Addamo G, Brandi H (2011) Vaginal fractional CO2 laser: a minimally invasive option for vaginal rejuvenation. Am J Cosm Surg 28:156–162
Zerbinati N, Serati M, Origoni M, Candiani M, Iannitti T, Salvatore S, Marotta F, Calligaro A (2015) Microscopic and ultrastructural modifications of postmenopausal atrophic vaginal mucosa after fractional carbon dioxide laser treatment. Lasers Med Sci 30:429–436
Salvatore S, Nappi RE, Parma M, Chionna R, Lagona F, Zerbinati N, Ferrero S, Origoni M, Candiani M, Leone Roberti Maggiore U (2015) Sexual function after fractional microablative CO2 laser in women with vulvovaginal atrophy. Climacteric 18:219–225
We thank DEKA M.E.L.A. S.r.l. for technical support.
Conflict of interest
The authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
About this article
Cite this article
Pieralli, A., Fallani, M.G., Becorpi, A. et al. Fractional CO2 laser for vulvovaginal atrophy (VVA) dyspareunia relief in breast cancer survivors. Arch Gynecol Obstet 294, 841–846 (2016). https://doi.org/10.1007/s00404-016-4118-6
- Vulvovaginal atrophy
- Oncological menopause
- Breast cancer survivors